<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573636</url>
  </required_header>
  <id_info>
    <org_study_id>PCS VIII</org_study_id>
    <nct_id>NCT02573636</nct_id>
  </id_info>
  <brief_title>The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy</brief_title>
  <official_title>The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and
      PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after
      biochemical failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and
      PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after
      biochemical failure.

      Patients in this study will be treated with standard hormonal treatment. Patients will remain
      on treatment regardless of rising PSA. PSA, other systemic therapy maybe added and the
      patients with oligometastasis could be treated with radiation therapy; this would be at the
      discretion of the treating oncologist.

      The primary endpoint of this study is to determine the predictive value of TMPRSS2-ERG gene
      fusion and PTEN in hormonal refractory free survival and clinical progression rate in three
      years. The secondary endpoints are to evaluate the relation between Gleason score and
      TMPRSS2-ERG gene fusion and PTEN independently and together, the relation between T stage and
      TMPRSS2-ERG gene fusion and PTEN independently and together, and to determine the association
      of these markers with overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">March 2041</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with biochemical failure showing coexistence of PTEN and TMPRSS2-ERG gene fusion.</measure>
    <time_frame>recruitment over 4 years</time_frame>
    <description>Biopsy samples of patients treated for high risk prostate cancer with radical radiation and hormonal therapy (LHRH) who have either clinical progression or 3-year hormonal refractory free survival will be tested to evaluate the predictive value of the coexistence of TMPRSS2-ERG gene fusion and the PTEN deletion. The results between the two groups will be compared to see if either DNA changes are an indicator of LHRH refractoriness</description>
  </primary_outcome>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Prostate Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Areas of prostate tumor will be identified by the pathologist of the study. This will then be
      excised from the paraffin block using a tissue microarray punch. Two punches will be
      acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted
      using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the isolation
      of nucleic acids will be used differing only in the time of protease digestion such that RNA
      is isolated after a short incubation (30 minutes), while DNA is isolated after a longer
      incubation (overnight). DNA will be used to assess copy number variation at the PTEN locus
      (10q23) using quantitative PCR and appropriate Taqman chemistry.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The original slides of 208 patients with informed consent will be reviewed. Patients with
        and without markers under the investigation will be accrued into this study. The
        investigators at the treating institutions will submit paraffin-embedded tissue blocks from
        the original pre-treatment diagnostic prostatic biopsy, which will be reviewed to confirm
        the Gleason score and to record other histopathologic features, such as the extent of tumor
        in the biopsies, the number of positive biopsies, and mitotic index.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T3a +

          -  PSA &gt; 20

          -  Gleason 8 or higher

          -  Karnofsky performance status ≥ 70.

          -  Signed study-specific informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Riggio</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>26771</phone_ext>
    <email>sriggio@jgh.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hugo Villeneuve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Bujold</last_name>
    </contact>
    <investigator>
      <last_name>Marjorie Jolicoeur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Tremblay</last_name>
    </contact>
    <investigator>
      <last_name>Levon Igidbashian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Roy-Huneault</last_name>
    </contact>
    <investigator>
      <last_name>Peter Vavassis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Riggio</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>26771</phone_ext>
      <email>sriggio@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC - Cedars Cancer Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianna Perna</last_name>
    </contact>
    <investigator>
      <last_name>Luis Souhami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
    </contact>
    <investigator>
      <last_name>Abdenour Nabid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Eve Caron</last_name>
    </contact>
    <investigator>
      <last_name>Linda-Suzanne Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josée Allard</last_name>
    </contact>
    <investigator>
      <last_name>André-Guy Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Tamim Niazi</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

